MS HEALTH National Prescription Audit"-‘ data for Pr telse Inhibitors, 1/00-12/O0.
RACEPT and Ago ron are registered trademarks of Agouron‘ Pharmaceuticals, Inc.
Copyright C 2001, Agouron Pharmaceuticals,!nc. All rights reserved. ‘f-V01 136-CC

A - A —A When choosing

plan V's .,mportant'to consider what

‘willfha,ve in the future. Studies show

CEPT early on leaves you with choices
t for later. Ask your doctor about
with VlRACEPT.y

nelfinavlr nfiesylate

tablets and oral powder

T is indicated in combination with
antiretroviral agents for the treat-

1‘ HIV infection. The most common
ct of VIRACEPT is diarrhea, which
ally be controlled with o\‘/er-the-
treatments. Some prescription
néprescription drugs and sup-

'nts should not be taken with

CEPT,\so talk to your ‘doctor first.

’ me people, protease inhibitors
een associated with the onset
rsening of diabetes mellitus
yperglycemia,~change.s in

be y fat, and increased bleeding
'n‘h_emophiliacs.r 

rmation; call toll
.88—V|vRA'CEPT or visit
iraceptcofm. ‘ i